WhiteOak Capital Pharma and Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (21-Jan-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹283 Cr
Expense Ratio
0.69%
ISIN
INF03VN01886
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
About this fund
As of 21-Jan-25, it has a Net Asset Value (NAV) of ₹13.25, Assets Under Management (AUM) of 282.62 Crores, and an expense ratio of 0.69%.
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 32.50% since inception.
- The fund's asset allocation comprises around 87.83% in equities, 0.00% in debts, and 12.17% in cash & cash equivalents.
- You can start investing in WhiteOak Capital Pharma and Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+32.50%
— (Cat Avg.)
Portfolio Summaryas of 31st December 2024
| Equity | ₹248.23 Cr | 87.83% |
| Others | ₹34.4 Cr | 12.17% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹25.14 Cr | 8.90% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹20.18 Cr | 7.14% |
| Divi's Laboratories Ltd | Equity | ₹17.69 Cr | 6.26% |
| Cipla Ltd | Equity | ₹16.17 Cr | 5.72% |
| Lupin Ltd | Equity | ₹13.84 Cr | 4.90% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹13.84 Cr | 4.90% |
| Fortis Healthcare Ltd | Equity | ₹9.28 Cr | 3.28% |
| Mankind Pharma Ltd | Equity | ₹9.25 Cr | 3.27% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹8.7 Cr | 3.08% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹8.06 Cr | 2.85% |
| Laurus Labs Ltd | Equity | ₹6.75 Cr | 2.39% |
| Ipca Laboratories Ltd | Equity | ₹6.73 Cr | 2.38% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹6.52 Cr | 2.31% |
| Piramal Pharma Ltd | Equity | ₹6.27 Cr | 2.22% |
| Biocon Ltd | Equity | ₹5.72 Cr | 2.02% |
| Poly Medicure Ltd | Equity | ₹5.52 Cr | 1.95% |
| Ami Organics Ltd | Equity | ₹4.89 Cr | 1.73% |
| Aurobindo Pharma Ltd | Equity | ₹4.59 Cr | 1.62% |
| Ajanta Pharma Ltd | Equity | ₹4.51 Cr | 1.60% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹4.51 Cr | 1.60% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.45 Cr | 1.57% |
| Neuland Laboratories Limited | Equity | ₹4.12 Cr | 1.46% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹4.03 Cr | 1.43% |
| Strides Pharma Science Ltd | Equity | ₹3.81 Cr | 1.35% |
| Sai Life Sciences Ltd | Equity | ₹3.61 Cr | 1.28% |
| Global Health Ltd | Equity | ₹3.59 Cr | 1.27% |
| Supriya Lifescience Ltd | Equity | ₹3.52 Cr | 1.25% |
| PB Fintech Ltd | Equity | ₹3.45 Cr | 1.22% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹3.42 Cr | 1.21% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.39 Cr | 1.20% |
| Shaily Engineering Plastics Ltd | Equity | ₹3.35 Cr | 1.18% |
| Onesource Specialty Pharma Limited ** | Equity | ₹3.28 Cr | 1.16% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹3.25 Cr | 1.15% |
| 91 DTB 03012025 | Bond - Gov't/Treasury | ₹3 Cr | 1.06% |
| 182 D Tbill Mat - 14/02/2025 | Bond - Gov't/Treasury | ₹2.98 Cr | 1.05% |
| Vimta Labs Ltd | Equity | ₹2.88 Cr | 1.02% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹2.85 Cr | 1.01% |
| Rainbow Childrens Medicare Ltd | Equity | ₹2.82 Cr | 1.00% |
| Dr Reddy's Laboratories Ltd | Equity | ₹2.72 Cr | 0.96% |
| Blue Jet Healthcare Ltd | Equity | ₹2.58 Cr | 0.91% |
| Shilpa Medicare Ltd | Equity | ₹2.56 Cr | 0.91% |
| Net Receivables / (Payables) | Cash | ₹2.18 Cr | 0.77% |
| 364 Day T-Bill 30.01.25 | Bond - Gov't/Treasury | ₹2.09 Cr | 0.74% |
| 91 Days Tbill Red 27-02-2025 | Bond - Gov't/Treasury | ₹1.98 Cr | 0.70% |
| Gufic Biosciences Ltd | Equity | ₹1.9 Cr | 0.67% |
| Thyrocare Technologies Ltd | Equity | ₹1.66 Cr | 0.59% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.32 Cr | 0.47% |
| Medplus Health Services Ltd | Equity | ₹1.14 Cr | 0.40% |
| 364 DTB 02052024 | Bond - Gov't/Treasury | ₹0.9 Cr | 0.32% |
| 182 DTB 20022025 | Bond - Gov't/Treasury | ₹0.89 Cr | 0.32% |
| Zota Health Care Ltd | Equity | ₹0.54 Cr | 0.19% |
| 364 DTB 09012025 | Bond - Gov't/Treasury | ₹0.1 Cr | 0.04% |
| 91 DTB 28032025 | Bond - Gov't/Treasury | ₹0.1 Cr | 0.03% |
Allocation By Market Cap (Equity)
Large Cap Stocks
29.53%
Mid Cap Stocks
25.50%
Small Cap Stocks
28.89%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹229.13 Cr | 81.07% |
| Basic Materials | ₹8.24 Cr | 2.91% |
| Financial Services | ₹3.45 Cr | 1.22% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Fund Managers
Piyush Baranwal
Since February 2024
Ramesh Mantri
Since February 2024
Dheeresh Pathak
Since February 2024
Naitik Shah
Since April 2024
Additional Scheme Detailsas of 31st December 2024
ISIN INF03VN01886 | Expense Ratio 0.69% | Exit Load 1.00% | Fund Size ₹283 Cr | Age 11 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹31.91 Cr | 30.7% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 23.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 21.6% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 28.7% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹230.79 Cr | 30.0% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹230.79 Cr | 27.5% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2863.52 Cr | 29.0% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2863.52 Cr | 27.2% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 27.4% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 28.5% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
Who manages the WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
- Piyush Baranwal
- Ramesh Mantri
- Dheeresh Pathak
- Naitik Shah
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (21-Jan-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹283 Cr
Expense Ratio
0.69%
ISIN
INF03VN01886
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
Risk Level
Your principal amount will be at Very High Risk
About this fund
As of 21-Jan-25, it has a Net Asset Value (NAV) of ₹13.25, Assets Under Management (AUM) of 282.62 Crores, and an expense ratio of 0.69%.
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 32.50% since inception.
- The fund's asset allocation comprises around 87.83% in equities, 0.00% in debts, and 12.17% in cash & cash equivalents.
- You can start investing in WhiteOak Capital Pharma and Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+32.50%
— (Cat Avg.)
Portfolio Summaryas of 31st December 2024
| Equity | ₹248.23 Cr | 87.83% |
| Others | ₹34.4 Cr | 12.17% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹25.14 Cr | 8.90% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹20.18 Cr | 7.14% |
| Divi's Laboratories Ltd | Equity | ₹17.69 Cr | 6.26% |
| Cipla Ltd | Equity | ₹16.17 Cr | 5.72% |
| Lupin Ltd | Equity | ₹13.84 Cr | 4.90% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹13.84 Cr | 4.90% |
| Fortis Healthcare Ltd | Equity | ₹9.28 Cr | 3.28% |
| Mankind Pharma Ltd | Equity | ₹9.25 Cr | 3.27% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹8.7 Cr | 3.08% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹8.06 Cr | 2.85% |
| Laurus Labs Ltd | Equity | ₹6.75 Cr | 2.39% |
| Ipca Laboratories Ltd | Equity | ₹6.73 Cr | 2.38% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹6.52 Cr | 2.31% |
| Piramal Pharma Ltd | Equity | ₹6.27 Cr | 2.22% |
| Biocon Ltd | Equity | ₹5.72 Cr | 2.02% |
| Poly Medicure Ltd | Equity | ₹5.52 Cr | 1.95% |
| Ami Organics Ltd | Equity | ₹4.89 Cr | 1.73% |
| Aurobindo Pharma Ltd | Equity | ₹4.59 Cr | 1.62% |
| Ajanta Pharma Ltd | Equity | ₹4.51 Cr | 1.60% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹4.51 Cr | 1.60% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.45 Cr | 1.57% |
| Neuland Laboratories Limited | Equity | ₹4.12 Cr | 1.46% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹4.03 Cr | 1.43% |
| Strides Pharma Science Ltd | Equity | ₹3.81 Cr | 1.35% |
| Sai Life Sciences Ltd | Equity | ₹3.61 Cr | 1.28% |
| Global Health Ltd | Equity | ₹3.59 Cr | 1.27% |
| Supriya Lifescience Ltd | Equity | ₹3.52 Cr | 1.25% |
| PB Fintech Ltd | Equity | ₹3.45 Cr | 1.22% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹3.42 Cr | 1.21% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.39 Cr | 1.20% |
| Shaily Engineering Plastics Ltd | Equity | ₹3.35 Cr | 1.18% |
| Onesource Specialty Pharma Limited ** | Equity | ₹3.28 Cr | 1.16% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹3.25 Cr | 1.15% |
| 91 DTB 03012025 | Bond - Gov't/Treasury | ₹3 Cr | 1.06% |
| 182 D Tbill Mat - 14/02/2025 | Bond - Gov't/Treasury | ₹2.98 Cr | 1.05% |
| Vimta Labs Ltd | Equity | ₹2.88 Cr | 1.02% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹2.85 Cr | 1.01% |
| Rainbow Childrens Medicare Ltd | Equity | ₹2.82 Cr | 1.00% |
| Dr Reddy's Laboratories Ltd | Equity | ₹2.72 Cr | 0.96% |
| Blue Jet Healthcare Ltd | Equity | ₹2.58 Cr | 0.91% |
| Shilpa Medicare Ltd | Equity | ₹2.56 Cr | 0.91% |
| Net Receivables / (Payables) | Cash | ₹2.18 Cr | 0.77% |
| 364 Day T-Bill 30.01.25 | Bond - Gov't/Treasury | ₹2.09 Cr | 0.74% |
| 91 Days Tbill Red 27-02-2025 | Bond - Gov't/Treasury | ₹1.98 Cr | 0.70% |
| Gufic Biosciences Ltd | Equity | ₹1.9 Cr | 0.67% |
| Thyrocare Technologies Ltd | Equity | ₹1.66 Cr | 0.59% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.32 Cr | 0.47% |
| Medplus Health Services Ltd | Equity | ₹1.14 Cr | 0.40% |
| 364 DTB 02052024 | Bond - Gov't/Treasury | ₹0.9 Cr | 0.32% |
| 182 DTB 20022025 | Bond - Gov't/Treasury | ₹0.89 Cr | 0.32% |
| Zota Health Care Ltd | Equity | ₹0.54 Cr | 0.19% |
| 364 DTB 09012025 | Bond - Gov't/Treasury | ₹0.1 Cr | 0.04% |
| 91 DTB 28032025 | Bond - Gov't/Treasury | ₹0.1 Cr | 0.03% |
Allocation By Market Cap (Equity)
Large Cap Stocks
29.53%
Mid Cap Stocks
25.50%
Small Cap Stocks
28.89%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹229.13 Cr | 81.07% |
| Basic Materials | ₹8.24 Cr | 2.91% |
| Financial Services | ₹3.45 Cr | 1.22% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Fund Managers
Piyush Baranwal
Since February 2024
Ramesh Mantri
Since February 2024
Dheeresh Pathak
Since February 2024
Naitik Shah
Since April 2024
Additional Scheme Detailsas of 31st December 2024
ISIN INF03VN01886 | Expense Ratio 0.69% | Exit Load 1.00% | Fund Size ₹283 Cr | Age 11 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹31.91 Cr | 30.7% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 23.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 21.6% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 28.7% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹230.79 Cr | 30.0% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹230.79 Cr | 27.5% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2863.52 Cr | 29.0% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2863.52 Cr | 27.2% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 27.4% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 28.5% |
Related Articles
Still got questions?
We're here to help.
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
Who manages the WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
- Piyush Baranwal
- Ramesh Mantri
- Dheeresh Pathak
- Naitik Shah
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts